-
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
•
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study for its SHP2 inhibitor BBP-398 in Chinese patients with advanced solid tumors. This marks a significant step forward in the development of BBP-398, which targets the SHP2 protein-tyrosine phosphatase. SHP2 links growth factor, cytokine, and…
-
Innovex Medical Files for IPO in Hong Kong to Boost Product Development
•
Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed an initial public offering (IPO) with the Hong Kong Stock Exchange. The IPO is co-sponsored by Goldman Sachs and CICC. While the price has not been disclosed at this stage, the proceeds will be used…
-
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a multi-center, open-label, dose escalation and expansion Phase I study. The study will assess the safety, pharmacokinetics, and efficacy of its embryonic ectoderm development (EED) inhibitor APG-5918. The drug…
-
Zai Lab Reports 33% YOY Revenue Growth in Q3 2022
•
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings report, showing total revenues of USD 57.5 million for the three-month period, up 33% year-on-year (YOY) and a 19% increase compared to USD 43.1 million for the same period in 2021. Research and Development (R&D)…
-
GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China
•
The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline (GSK, NYSE: GSK) and the Chinese Association of STD and AIDS Prevention and Control (CASPC). The collaboration is part of an HIV Sustained Care Advocacy project initiated by the UK major and its joint venture…
-
3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing
•
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has accepted another market filing for its recombinant thrombopoietin for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. This marks a significant step forward in expanding the therapeutic indications for…
-
Boston Scientific Partners with Omron for Atrial Fibrillation Management
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at the 5th China International Import Expo (CIIE). The collaboration is focused on enhancing the management of cardiovascular and cerebrovascular diseases, particularly atrial fibrillation. The two companies will integrate their product and resource advantages to bolster…
-
Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE
•
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda Pharmaceutical Co., Ltd (TYO: 4502) and US firms Amazon Web Services (AWS) and Accenture. The collaboration also marks the initiation of “TakedaSpark+”, an innovation incubation platform launched by the Japan-based firm in 2021. Through this…
-
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase II/III study for its third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) BPI-D0316. The study evaluated the drug as a first-line treatment for naïve locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR…
-
BeiGene Reports 88% YOY Revenue Growth in Q3 2022
•
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings report, showing robust growth with revenues reaching USD 387.6 million, an 88% year-on-year (YOY) expansion. Sales from products totaled USD 349.5 million during the period, up 82% YOY, driven primarily by Brukinsa (zanubrutinib) and the…
-
Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE
•
A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer Care AG was unveiled at the 5th China International Import Expo (CIIE) meeting. The collaboration aims to leverage the respective strengths of both companies to construct new mechanisms of cooperation in the medical and healthcare…
-
Medtronic Partners with Shanghai JiaHui Hospital at CIIE
•
US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled at the 5th China International Import Expo (CIIE) held this week. The collaboration aims to enhance patient services, upgrade supply chains, and implement clinical solutions, among other initiatives. Financial details of the partnership were not…
-
ChainGen Bio Raises RMB 45M in Angel Round for X-oligo Conjugates Development
•
ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million (USD 6.2 million) in an angel financing round co-led by Matrix Partners and Frees Fund. The proceeds will be used to advance pipeline research and development, patent layout, and company operations, including laboratory platform construction.…
-
Yibao Technology Secures Series A+ Funding to Expand Health Insurance Services
•
Yibao Technology Co., Ltd, a Shanghai-based service provider for city-level supplementary commercial insurance (“Huiminbao”) schemes, has reportedly raised an undisclosed amount in a Series A+ financing round. The round was led by China Resources Pharmaceutical Group Ltd, China Resources Medicine Commercial Holdings Ltd, and China Resources Sanjiu Medical & Pharmaceutical…
-
Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing for its drug candidate HSK16149, intended for the treatment of diabetic peripheral neuropathic pain (DPNP), has been accepted for review by the National Medical Products Administration (NMPA). HSK16149 is an in-house Category 1 drug being…
-
Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE
•
Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th China International Import Expo (CIIE), aimed at enhancing precision whole disease course management services for cancer patients. The collaboration focuses on improving accessibility to novel cancer treatments and other health services, particularly for patients with…
-
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
•
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its ACYW135 meningococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis of groups A, C, Y, and W135.…
-
Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the enrollment of the first patients for its ZKY001 in a Phase II clinical study in transepithelial photorefractive keratectomy (TPRK). The study will enroll 120 patients across 10 centers. Additionally, a separate Phase II clinical…
-
Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a licensing agreement with South Korea’s C&V Tech, a glaucoma device firm. The agreement grants Zhaoke exclusive rights for registration, import, promotion, distribution, marketing, and sales of C&V Tech’s TONO-i tonometer in Greater China. No…
